Latest Ratios: P/E Ratio -1.0x · EV/EBITDA N/A · ROE -198.1%. (2001–2025 historical series)
Price-based multiples — how expensive the stock is relative to earnings, sales, book value, and cash flow
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Market Cap | $5M | $6M | $3M | $17M | $141M | $234M | $528M | $793M | $268M | $567M | $698M |
| Enterprise Value | $4M | $5M | $2M | $11M | $122M | $188M | $418M | $715M | $207M | $496M | $617M |
| P/E Ratio → | -1.00 | — | — | — | — | — | — | — | — | — | — |
| P/S Ratio | 1074.54 | 1258.64 | 305.84 | 3394.19 | 48.24 | 587.17 | — | — | 1838.09 | 88.73 | 101.68 |
| P/B Ratio | 1.99 | 2.92 | 1.48 | 2.69 | 3.66 | 4.03 | 4.26 | 8.34 | 3.14 | — | — |
| P/FCF | — | — | — | — | — | — | — | — | — | — | — |
| P/OCF | — | — | — | — | — | — | — | — | — | — | — |
P/E links to full P/E history page with 30-year chart
Enterprise-value multiples — capital-structure-neutral measures of total business value
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| EV / Revenue | — | 981.64 | 196.74 | 2181.79 | 41.74 | 471.70 | — | — | 1415.29 | 77.63 | 89.86 |
| EV / EBITDA | — | — | — | — | — | — | — | — | — | — | — |
| EV / EBIT | — | — | — | — | — | — | — | — | — | — | — |
| EV / FCF | — | — | — | — | — | — | — | — | — | — | — |
Margins and return-on-capital ratios measuring operating efficiency
Full margin charts and quarterly trend are on the Earnings History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | 100.0% | 100.0% | 100.0% | -95960.0% | 100.0% | 100.0% | — | — | 100.0% | 100.0% | 100.0% |
| Operating Margin | -84500.0% | -84500.0% | -48120.0% | -685340.0% | -1201.4% | -19484.7% | — | — | -36921.9% | -837.3% | -2409.4% |
| Net Profit Margin | -83520.0% | -83520.0% | -46790.0% | -702800.0% | -1291.2% | -19786.7% | — | — | -36381.5% | -850.3% | -2409.2% |
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| ROE | -198.1% | -198.1% | -111.8% | -156.7% | -78.1% | -86.5% | -73.0% | -130.5% | -62.1% | — | -3282.0% |
| ROA | -146.0% | -146.0% | -84.9% | -96.0% | -47.2% | -65.3% | -62.6% | -115.4% | -52.9% | -51.3% | -127.1% |
| ROIC | -364.2% | -364.2% | -593.1% | -259.5% | -166.3% | -450.4% | -384.5% | -209.3% | — | — | — |
| ROCE | -200.4% | -200.4% | -115.0% | -145.6% | -58.7% | -75.0% | -71.6% | -63.5% | -63.3% | -61.0% | -146.2% |
Solvency and debt-coverage ratios — lower is generally safer
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Debt / Equity | — | — | — | — | 0.52 | 0.52 | 0.04 | 0.02 | — | — | — |
| Debt / EBITDA | — | — | — | — | — | — | — | — | — | — | — |
| Net Debt / Equity | — | -0.64 | -0.53 | -0.96 | -0.49 | -0.79 | -0.89 | -0.81 | -0.72 | — | — |
| Net Debt / EBITDA | — | — | — | — | — | — | — | — | — | — | — |
| Debt / FCF | — | — | — | — | — | — | — | — | — | — | — |
| Interest Coverage | — | — | — | -17.29 | -10.96 | -65.23 | — | — | — | -64.45 | — |
Net cash position: cash ($1M) exceeds total debt ($0)
Short-term solvency ratios and asset-utilisation metrics
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 2.45 | 2.45 | 3.98 | 4.22 | 2.23 | 4.91 | 7.11 | 8.42 | 8.89 | 4.35 | 6.63 |
| Quick Ratio | 2.45 | 2.45 | 3.98 | 4.22 | 1.65 | 4.91 | 7.11 | 8.42 | 8.89 | 4.35 | 6.63 |
| Cash Ratio | 1.70 | 1.70 | 1.58 | 3.10 | 1.62 | 4.74 | 6.26 | 6.37 | 6.51 | 3.40 | 5.13 |
| Asset Turnover | — | 0.00 | 0.00 | 0.00 | 0.04 | 0.00 | — | — | 0.00 | 0.06 | 0.06 |
| Inventory Turnover | — | — | — | — | — | — | — | — | — | — | — |
| Days Sales Outstanding | — | 219.00 | 182.50 | 73.00 | 0.50 | 1018.88 | — | — | 4660.00 | 1.09 | 1.12 |
Earnings, FCF, buyback, and dividend yields — total returns to shareholders
Full dividend history and growth charts are on the Dividend History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Dividend Yield | — | — | — | — | — | — | — | — | 6.3% | — | 1.0% |
| Payout Ratio | — | — | — | — | — | — | — | — | — | — | — |
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Earnings Yield | — | — | — | — | — | — | — | — | — | — | — |
| FCF Yield | — | — | — | — | — | — | — | — | — | — | — |
| Buyback Yield | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.1% | 0.6% | 0.4% | 0.2% |
| Total Shareholder Yield | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.1% | 6.9% | 0.4% | 1.2% |
| Shares Outstanding | — | $2M | $2M | $2M | $1M | $1M | $1M | $1M | $956724 | $912921 | $869276 |
Imminent liquidity insolvency risk
According to current market data, TCRT trades at a price-to-sales ratio of 1069.66, a figure that is statistically meaningless given the company's near-zero revenue and suggests the market is pricing the equity as a speculative option on a potential reverse-merger or liquidation event rather than fundamental operations.
The extreme P/S multiple highlights the total disconnect between the company's market capitalization and its underlying commercial reality. Investors should interpret this valuation as a reflection of the firm's status as a distressed shell, where the primary value driver is the potential for intellectual property monetization rather than any expectation of future earnings growth.
As reported in historical financial statements, the company's ROIC has consistently remained in deep negative territory, with recent figures such as -89.2% in 2026Q1 indicating that every dollar of invested capital is being destroyed rather than compounded through the firm's clinical-stage research activities.
The persistent decay in returns on invested capital underscores the structural inability of the current business model to generate value from its research expenditures. This trend suggests that the company's capital allocation strategy has failed to reach the necessary clinical milestones required to achieve a positive return profile, leaving shareholders with significant value erosion.
Based on reported figures, the company's accounts payable turnover has shown extreme volatility, with DPO reaching 5,698 days in 2026Q1, which suggests that the firm is likely delaying payments to vendors as a reactive measure to manage its critically low cash position.
The erratic nature of these efficiency metrics is characteristic of a company in a liquidity crisis, where operational focus has shifted from optimizing the cash conversion cycle to mere survival. Such extreme DPO levels warrant further investigation into potential vendor disputes or the exhaustion of credit terms with critical service providers.
As indicated by the most recent quarterly filings, the company's current ratio has fluctuated significantly, dropping to 1.63 in 2026Q1, which provides a misleading sense of security given the rapid depletion of cash reserves and the lack of any meaningful incoming revenue streams to cover ongoing obligations.
While a current ratio above 1.0 might typically suggest adequate short-term liquidity, the absolute dollar value of the company's cash and equivalents is insufficient to sustain operations for any extended period. Investors should monitor the company's ability to meet its immediate contractual liabilities, as the current liquidity position appears highly vulnerable to even minor operational shocks.
The price-to-book ratio of 1.98 is the most commonly misapplied metric for this business model, as it erroneously implies that the company's book value represents tangible assets that could be recovered in a liquidation scenario, ignoring the high probability of significant impairment to its intellectual property.
Using P/B to value a distressed biotech entity like TCRT obscures the reality that the firm's book value is largely composed of capitalized R&D costs that may hold little to no market value in a wind-down. Analysts should instead focus on a liquidation-adjusted net cash position, which provides a more accurate assessment of the potential recovery for shareholders.
Includes 30+ ratios · 25 years · Updated daily
DCF models, multiple analysis, and analyst estimates.
10-year return with dividends reinvested.
See how regular investing compounds over time.
Compare growth, multiples, and margins vs sector.
Quick answers to the most common questions about buying TCRT stock.
Alaunos Therapeutics, Inc.'s current P/E ratio is -1.0x. This places it at the 50th percentile of its historical range.
Alaunos Therapeutics, Inc.'s return on equity (ROE) is -198.1%. The historical average is -122.6%.
Based on historical data, Alaunos Therapeutics, Inc. is trading at a P/E of -1.0x. This is at the 50th percentile of its historical P/E range. Compare with industry peers and growth rates for a complete picture.
Alaunos Therapeutics, Inc. has 100.0% gross margin and -84500.0% operating margin.